These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8913832)

  • 1. Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis.
    Stewart DJ; Raaphorst GP; Yau J; Beaubien AR
    Invest New Drugs; 1996; 14(2):115-30. PubMed ID: 8913832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent use of multiple low dose chemotherapy agents with differing mechanisms of action as a strategy vs passive resistance: A pilot study.
    Stewart DJ; Goel R; Gertler SZ; Huan S; Tomiak EM; Yau J; Cripps C; Evans WK
    Int J Oncol; 1999 Oct; 15(4):693-9. PubMed ID: 10493950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
    Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy.
    Canal P; Gamelin E; Vassal G; Robert J
    Pathol Oncol Res; 1998; 4(3):171-8. PubMed ID: 9761935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression.
    Blumenthal RD; Leone E; Goldenberg DM; Rodriguez M; Modrak D
    Int J Cancer; 2004 Jan; 108(2):293-300. PubMed ID: 14639618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance to cisplatin and carboplatin.
    Stewart DJ
    Crit Rev Oncol Hematol; 2007 Jul; 63(1):12-31. PubMed ID: 17336087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The possible role of chemotherapy in antiangiogenic drug resistance.
    Bocci G; Loupakis F
    Med Hypotheses; 2012 May; 78(5):646-8. PubMed ID: 22365648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice.
    Polin L; White K; Kushner J; Paluch J; Simpson C; Pugh S; Edelstein MK; Hazeldine S; Fontana J; LoRusso P; Horwitz JP; Corbett TH
    Invest New Drugs; 2002 Feb; 20(1):13-22. PubMed ID: 12003190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current options in treatment of anthracycline-resistant breast cancer.
    Kröger N; Achterrath W; Hegewisch-Becker S; Mross K; Zander AR
    Cancer Treat Rev; 1999 Oct; 25(5):279-91. PubMed ID: 10544072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model.
    Pusztai L; Siddik ZH; Mills GB; Bast RC
    Acta Oncol; 1998; 37(7-8):629-40. PubMed ID: 10050979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
    Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
    Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.
    Falgreen S; Dybkær K; Young KH; Xu-Monette ZY; El-Galaly TC; Laursen MB; Bødker JS; Kjeldsen MK; Schmitz A; Nyegaard M; Johnsen HE; Bøgsted M
    BMC Cancer; 2015 Apr; 15():235. PubMed ID: 25881228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical drug resistance: the role of factors other than P-glycoprotein.
    Kaye SB
    Am J Med; 1995 Dec; 99(6A):40S-44S. PubMed ID: 8585535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute in vivo resistance in high-dose therapy.
    Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
    Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.